Huntington Ingalls Industries Inc
Change company Symbol lookup
Select an option...
HII Huntington Ingalls Industries Inc
BABA Alibaba Group Holding Ltd
ABBV Abbvie Inc
OBMP OncBioMune Pharmaceuticals Inc
AVNW Aviat Networks Inc
AMPY Amplify Energy Corp
JEPI JPMorgan Equity Premium Income ETF
VOLAF Volvo AB
AGNC Agnc Investment Corp
GME GameStop Corp
Go

Industrials : Aerospace & Defense | Mid Cap Value
Company profile

Huntington Ingalls Industries, Inc. is a military shipbuilding company and a provider of professional services to partners in government and industry. The Company's business consists of the design, construction, repair and maintenance of nuclear-powered ships and non-nuclear ships for the United States Navy and coastal defense surface ships for the United States Coast Guard, as well as the refueling and overhaul and inactivation of nuclear-powered ships for the United States Navy. It operates through three segments: Ingalls Shipbuilding (Ingalls), Newport News Shipbuilding (Newport News) and Technical Solutions. Its Ingalls segment includes its non-nuclear ship design, construction, repair and maintenance businesses. Its Newport News includes all of its nuclear ship design, construction, overhaul, refueling, and repair and maintenance businesses. Its Technical Solutions segment provides a range of professional services to the governmental and energy markets.

Closing Price
$208.06
Day's Change
-0.29 (-0.14%)
Bid
--
Ask
--
B/A Size
--
Day's High
210.00
Day's Low
206.18
Volume
(Average)
Volume:
274,074

10-day average volume:
303,432
274,074

Astrotech's stock skyrockets after JDA with Cleveland Clinic to develop COVID-19 breath test

8:52 am ET October 21, 2020 (MarketWatch)
Print

Shares of Astrotech Corp. (ASTC) skyrocketed 168% in active trading to pace all premarket gainers Wednesday, after the company said its BreathTech Corp. subsidiary has partnered with the Cleveland Clinic to develop a rapid breath test for COVID-19. Trading volume was 11.4 million shares ahead of the open, compared with the full-day average of about 1.4 million shares. The stock is on track to open at the highest price seen during regular-session hours since April, in the aftermath of the company's announcement in March (http://www.marketwatch.com/story/astrotechs-stock-rockets-6-fold-on-heavy-volume-as-company-develops-breath-test-for-lung-infections-2020-03-25) that it was developing a breath test that could screen for lung infections, including the COVID-19 virus. Astrotech said late Tuesday that BreathTech sighed a joint development agreement (JDA) with Cleveland Clinic to explore leveraging the BreathTest-1000 mass spectrometer to rapidly screen for COVID-19. "The advantage of breath testing is that it is non-invasive and non-intrusive," said Dr. Raed Dweik, chairman of Cleveland Clinic's Respiratory Institute. "It does not have a dose limitation like x-rays, an amount limitation like blood or saliva tests, or a timing limitation like PCR, blood and urine tests." Astrotech's stock has lost 6.1% year to date through Tuesday, while the S&P 500 has gained 6.6%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 21, 2020 08:52 ET (12:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.